Patents Assigned to Elan Pharmaceuticals, Inc.
  • Macrocycles useful in the treatment of alzheimer's disease
    Patent number: 7456163
    Abstract: The present invention is macrocycles of the formula (X): for treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme for the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
    Type: Grant
    Filed: August 19, 2005
    Date of Patent: November 25, 2008
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Shon R. Pulley, James P. Beck, Ruth E. TenBrink, Jon S. Jacobs
  • Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
    Patent number: 7452912
    Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: December 11, 2002
    Date of Patent: November 18, 2008
    Assignees: Elan Pharmaceuticals, Inc., Wyeth
    Inventors: Francine S. Grant, Andrei W. Konradi, Michael A. Pleiss, Eugene D. Thorsett
  • Crystals of unliganded beta secretase and/or beta secretase-like proteins and the use thereof
    Patent number: 7442537
    Abstract: The x-ray crystal structure of BACE or BACE-like proteins is useful for solving the structure of other molecules or molecular complexes, and identifying and/or designing potential modifiers of BACE activity.
    Type: Grant
    Filed: May 9, 2003
    Date of Patent: October 28, 2008
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Timothy E. Benson, Daisy Danielle Woods, Donald Bryan Prince
  • Substituted pyrazole derivatives and related compounds as bradykinin Breceptor antagonists
    Patent number: 7432379
    Abstract: Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
    Type: Grant
    Filed: April 30, 2004
    Date of Patent: October 7, 2008
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Jay S. Tung, Albert W. Garofalo, Michael A. Pleiss, Jing Wu, David W. G. Wone, Ashley C. Guinn, Darren B. Dressen, R. Jeffrey Neitz, Jennifer Marugg, Martin Neitzel
  • Compounds for the treatment of Alzheimer's disease
    Patent number: 7432389
    Abstract: The present invention is substituted amine s of formula (XV) useful in treating Alzheimer's ease and other similar disease.
    Type: Grant
    Filed: March 7, 2006
    Date of Patent: October 7, 2008
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Lawrence Fang, Varghese John
  • Beta-secretase enzyme compositions and methods
    Patent number: 7427478
    Abstract: Disclosed are various forms of an active, isolated ?-secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease. Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (?-APPwt and ?-APPsw) are also disclosed, as are antibodies directed to such proteins. These compositions are useful for use in methods of selecting compounds that modulate ?-secretase. Inhibitors of ?-secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease.
    Type: Grant
    Filed: February 28, 2005
    Date of Patent: September 23, 2008
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: John P. Anderson, Guriqbal Basi, Minh Tam Doan, Normand Frigon, Varghese John, Michael Power, Sukanto Sinha, Gwen Tatsuno, Jay Tung, Shuwen Wang, Lisa McConlogue
  • Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-? peptide (x-?41) and tau
    Patent number: 7427392
    Abstract: This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid-? peptide (x??41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. Low levels of the peptide are consistent with the disease and, with other tests, can provide a positive diagnosis. Other methods involve measuring the amounts of both A?(x??41) and tau. Low levels of A?(x??41) and high levels of tau are a positive indicator of Alzheimer's disease, while high levels of A?(x??41) and low levels of tau are a negative indication of Alzheimer's disease.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 23, 2008
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Peter A. Seubert, Carmen Vigo-Pelfrey, Dale B. Schenk, Robin Barbour
  • Heterocyclic compounds which inhibit leukocyte adhesion mediated by ?integrins
    Patent number: 7427628
    Abstract: Disclosed are compounds which bind ?4 integrins, preferably VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by ?4 integrins, preferably VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: September 26, 2006
    Date of Patent: September 23, 2008
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Andrei W. Konradi, Christopher M. Semko, Ying-zi Xu, Frank Stappenbeck, Brian P. Stupi, Jenifer Smith, Michael A. Pleiss, Eugene D. Thorsett
  • 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin Breceptor antagonists for the treatment of inflammatory diseases
    Patent number: 7417152
    Abstract: Disclosed are compounds of formula I and II that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
    Type: Grant
    Filed: April 30, 2004
    Date of Patent: August 26, 2008
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Jay S. Tung, Albert W. Garofalo, Michael A. Pleiss, Jing Wu, David W. G. Wone, Ashley C. Guinn, Darren B. Dressen, R. Jeffrey Neitz, Jennifer Marugg, Martin Neitzel
  • Prevention And Treatment of Synucleinopathic And Amyloidogenic Disease
    Publication number: 20080175838
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Application
    Filed: August 20, 2007
    Publication date: July 24, 2008
    Applicants: Elan Pharmaceuticals, Inc., The Regents of the University of California
    Inventors: Dale B. Schenk, Kate Dora Games, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Eliezar Masliah
  • Methods of Treatment of Amyloidosis Using Subsituted Ethanolcyclicamine Aspartyl Protease Inhibitors
    Publication number: 20080166332
    Abstract: The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis.
    Type: Application
    Filed: August 26, 2005
    Publication date: July 10, 2008
    Applicant: ELAN PHARMACEUTICALS, INC.
    Inventors: Roy Hom, Lawrence Fang, Varghese John
  • ALPHA-SYNUCLEIN KINASE
    Publication number: 20080160011
    Abstract: The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 and GRK6 kinases.
    Type: Application
    Filed: January 30, 2007
    Publication date: July 3, 2008
    Applicant: Elan Pharmaceuticals, Inc.
    Inventors: Tami J. Chilcote, Kelly Banducci, Normand L. Frigon, Guriqbal S. Basi, John P. Anderson, Jason Goldstein, Irene Griswold-Prenner, David Chereau
  • A-BETA IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
    Publication number: 20080145373
    Abstract: The present invention is directed to methods of producing conjugates of A? peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on amino acid residues of the carrier or of the optionally attached linker molecule, and wherein any unconjugated reactive functional groups on amino acid residues are inactivated via capping, thus retaining the immunological functionality of the carrier molecule, but reducing the propensity for undesirable reactions that could render the conjugate less safe or effective. Furthermore, the invention also relates to such immunogenic products and immunogenic compositions containing such immunogenic products made by such methods.
    Type: Application
    Filed: August 20, 2007
    Publication date: June 19, 2008
    Applicants: Elan Pharmaceuticals, Inc., Wyeth
    Inventors: Rasappa G. Arumugham, A. Krishna Prasad
  • Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
    Patent number: 7385085
    Abstract: The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
    Type: Grant
    Filed: July 11, 2005
    Date of Patent: June 10, 2008
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Varghese John, Michel Maillard, Barbara Jagodzinska, Jose Aquino, Gary Probst, Jay Tung
  • 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
    Patent number: 7365073
    Abstract: Disclosed are certain 3-(heteroaryl)alanine derivatives which bind VLA-4 and inhibit leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: April 29, 2008
    Assignees: Elan Pharmaceuticals, Inc., Wyeth
    Inventors: Andrei W. Konradi, Michael A. Pleiss, Eugene D. Thorsett, Darren B. Dressen, Francine S. Farouz, Christopher Semko, Ying-Zi Xu, Frank Stappenbeck
  • Substituted aminoalcohols useful in treatment of Alzheimer's disease
    Patent number: 7361688
    Abstract: The invention provides compounds of formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: April 22, 2008
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Michel Maillard, John A. Tucker
  • Truncated fragments of alpha-synuclein in Lewy body disease
    Patent number: 7358331
    Abstract: The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.
    Type: Grant
    Filed: July 29, 2005
    Date of Patent: April 15, 2008
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Tamie J Chilcote, Jason Goldstein, John P Anderson, Donald Walker
  • Substituted ureas and carbamates
    Patent number: 7351738
    Abstract: The invention provides compounds of formula I: useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
    Type: Grant
    Filed: November 26, 2003
    Date of Patent: April 1, 2008
    Assignees: Elan Pharmaceuticals, Inc., Pharmacia & Upjohn Company
    Inventors: Shon R. Pulley, John A. Tucker
  • Bridged N-cyclic sulfonamido inhibitors of gamma secretase
    Patent number: 7345056
    Abstract: The invention provides N-cyclic sulfonamido compounds and salts of Formula I: wherein A is as described in the specification and R1 and R2 combine to form a [3.3.1] or a [3.2.1] ring system, where the nitrogen is attached to the two bridgehead carbons, and the [3.3.1] or [3.2.1] ring systems are optionally fused with an heteroaryl or heterocycloalkyl ring. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's Disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of treating cognitive disorders, such as Alzheimer's disease, and the intermediates useful in preparing the compounds of Formula I.
    Type: Grant
    Filed: August 18, 2006
    Date of Patent: March 18, 2008
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Simeon Bowers, Albert W. Garofalo, Roy K. Hom, Andrei W. Konradi, Matthew N. Mattson, Martin L. Neitzel, Christopher M. Semko, Anh P. Truong, Jing Wu, Ying-zi Xu
  • 3,4-disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines
    Patent number: 7338965
    Abstract: The invention relates to substituted piperidine, piperazine, morpholine and thiomorpholine compounds useful in the treatment of Alzheimer's disease and more specifically to compounds that are capable of inhibiting beta-secretase, an enzyme that cleaves amyloid precursor protein to produce amyloid beta peptide (A-beta), a major component of the amyloid plaques found in the brains of Alzheimer's sufferers. One embodiment of the invention relates to compounds having the structure: where Z is CR or N, and R1, R2 and R3 are as described in the specification.
    Type: Grant
    Filed: November 19, 2002
    Date of Patent: March 4, 2008
    Assignees: Pharmacia & Upjohn Company, Elan Pharmaceuticals, Inc.
    Inventors: Joseph B. Moon, Shon R. Pulley, Daniel H. Rich, David L. Brown, Barbara Jagodzinska, Varghese John, John Jacobs